Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Chief Medical Officer | September 15, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,667 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 116,667 · Balance 116,667 F1: Represents restricted stock units ("RSUs") which vest as follows: 10,400 RSUs vest on January 1, 2027, prorated from August 24, 2026, the vesting start date, and the remaining RSUs vest in equal annual installments on each January 1, 2028, January 1, 2029 and January 1, 2030, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Stock Option (right to by)SEC Table II · derivative / convertible security · Conversion / exercise price $5.36 · Expires 2036-09-14 | Direct | 233,333 |
Reported balance
After 2026-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-15 · Grant · Acquired 233,333 · Balance 233,333 F2: The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") which vest as follows: 10,400 RSUs vest on January 1, 2027, prorated from August 24, 2026, the vesting start date, and the remaining RSUs vest in equal annual installments on each January 1, 2028, January 1, 2029 and January 1, 2030, subject to the Reporting Person's continuous service through each applicable vesting date.
F2: The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 21:35 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to by) · Derivative | 233,333 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001193125-26-393274 · ownership.xml · derivative · entry 2 Trenor Cameron C. III · CIK 0002150478 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,333 Underlying: Common Stock · 233,333 shares Expires 2036-09-14 F2 · derivative.exercise_date: The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 21:35 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 116,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-393274 · ownership.xml · nonDerivative · entry 1 Trenor Cameron C. III · CIK 0002150478 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,667 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 10,400 RSUs vest on January 1, 2027, prorated from August 24, 2026, the vesting start date, and the remaining RSUs vest in equal annual installments on each January 1, 2028, January 1, 2029 and January 1, 2030, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.